Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 4
1953 2
1955 2
1956 2
1957 1
1958 2
1959 2
1960 2
1962 2
1963 2
1964 1
1965 9
1966 5
1967 4
1968 9
1969 9
1970 5
1971 6
1972 3
1973 4
1974 6
1975 5
1976 7
1977 19
1978 14
1979 13
1980 10
1981 16
1982 29
1983 20
1984 22
1985 13
1986 14
1987 32
1988 22
1989 14
1990 26
1991 13
1992 10
1993 21
1994 27
1995 17
1996 14
1997 22
1998 27
1999 25
2000 24
2001 23
2002 25
2003 39
2004 50
2005 58
2006 42
2007 62
2008 45
2009 74
2010 67
2011 69
2012 63
2013 62
2014 77
2015 66
2016 65
2017 80
2018 57
2019 73
2020 94
2021 71
2022 68
2023 87
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

1,824 results

Results by year

Filters applied: . Clear all
Page 1
A non-canonical vitamin K cycle is a potent ferroptosis suppressor.
Mishima E, Ito J, Wu Z, Nakamura T, Wahida A, Doll S, Tonnus W, Nepachalovich P, Eggenhofer E, Aldrovandi M, Henkelmann B, Yamada KI, Wanninger J, Zilka O, Sato E, Feederle R, Hass D, Maida A, Mourão ASD, Linkermann A, Geissler EK, Nakagawa K, Abe T, Fedorova M, Proneth B, Pratt DA, Conrad M. Mishima E, et al. Among authors: ito j. Nature. 2022 Aug;608(7924):778-783. doi: 10.1038/s41586-022-05022-3. Epub 2022 Aug 3. Nature. 2022. PMID: 35922516 Free PMC article.
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffmann KG, Smith C. Baden LR, et al. Among authors: ito ji. J Natl Compr Canc Netw. 2016 Jul;14(7):882-913. doi: 10.6004/jnccn.2016.0093. J Natl Compr Canc Netw. 2016. PMID: 27407129
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K. Yamasoba D, et al. Among authors: ito j. Cell. 2022 Jun 9;185(12):2103-2115.e19. doi: 10.1016/j.cell.2022.04.035. Epub 2022 May 2. Cell. 2022. PMID: 35568035 Free PMC article.
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, Morioka Y, Nao N, Nasser H, Uriu K, Kosugi Y, Tsuda M, Orba Y, Sasaki M, Shimizu R, Kawabata R, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Ikeda T, Irie T, Matsuno K, Tanaka S, Fukuhara T, Sato K. Suzuki R, et al. Among authors: ito j. Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1. Nature. 2022. PMID: 35104835 Free PMC article.
Virological characteristics of the SARS-CoV-2 JN.1 variant.
Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Hinay AA Jr, Chen L, Plianchaisuk A, Kobiyama K, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Zahradnik J, Ito J, Sato K. Kaku Y, et al. Among authors: ito j. Lancet Infect Dis. 2024 Feb;24(2):e82. doi: 10.1016/S1473-3099(23)00813-7. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184005 No abstract available.
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.
Yamasoba D, Uriu K, Plianchaisuk A, Kosugi Y, Pan L, Zahradnik J; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Sato K. Yamasoba D, et al. Among authors: ito j. Lancet Infect Dis. 2023 Jun;23(6):655-656. doi: 10.1016/S1473-3099(23)00278-5. Epub 2023 May 3. Lancet Infect Dis. 2023. PMID: 37148902 Free PMC article. No abstract available.
International consensus (ICON) on treatment of sudden sensorineural hearing loss.
Marx M, Younes E, Chandrasekhar SS, Ito J, Plontke S, O'Leary S, Sterkers O. Marx M, et al. Among authors: ito j. Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Feb;135(1S):S23-S28. doi: 10.1016/j.anorl.2017.12.011. Epub 2018 Feb 1. Eur Ann Otorhinolaryngol Head Neck Dis. 2018. PMID: 29396226 Free article.
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, Kobiyama K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K. Kimura I, et al. Among authors: ito j. Cell. 2022 Oct 13;185(21):3992-4007.e16. doi: 10.1016/j.cell.2022.09.018. Epub 2022 Sep 14. Cell. 2022. PMID: 36198317 Free PMC article.
1,824 results